My NCBISign In
Logo of brjclinpharmLink to Publisher's site

Volume 71(5);  May 2011

Editors' View

Allergy, pseudo-allergy and non-allergy
Derek G Waller
Br J Clin Pharmacol. 2011 May; 71(5): 637–638. doi: 10.1111/j.1365-2125.2011.03976.x
PMCID:
PMC3093068
Full Text PDF–346K

New Drug Mechanisms

Rilonacept and canakinumab
Eline A Dubois, Robert Rissmann, Adam F Cohen
Br J Clin Pharmacol. 2011 May; 71(5): 639–641. doi: 10.1111/j.1365-2125.2011.03958.x
Correction in:
Br J Clin Pharmacol. 2011 August; 72(2): 365.
PMCID:
PMC3093069
Full Text PDF–516K Correction

Drug Allergy: Themed Section

General principles of investigating and managing drug allergy
Anthony Frew
Br J Clin Pharmacol. 2011 May; 71(5): 642–646. doi: 10.1111/j.1365-2125.2011.03933.x
PMCID:
PMC3093070
Abstract Full Text PDF–514K
Peri-operative anaphylaxis
Linda Nel, Efrem Eren
Br J Clin Pharmacol. 2011 May; 71(5): 647–658. doi: 10.1111/j.1365-2125.2011.03913.x
PMCID:
PMC3093071
Abstract Full Text PDF–891K
Hypersensitivity reactions to HIV therapy
Mas Chaponda, Munir Pirmohamed
Br J Clin Pharmacol. 2011 May; 71(5): 659–671. doi: 10.1111/j.1365-2125.2010.03784.x
PMCID:
PMC3093072
Abstract Full Text PDF–1.0M
Skin manifestations of drug allergy
Michael R Ardern-Jones, Peter S Friedmann
Br J Clin Pharmacol. 2011 May; 71(5): 672–683. doi: 10.1111/j.1365-2125.2010.03703.x
PMCID:
PMC3093073
Abstract Full Text PDF–1.2M
Epidemiology and risk factors for drug allergy
Bernard Y-H Thong, Teck-Choon Tan
Br J Clin Pharmacol. 2011 May; 71(5): 684–700. doi: 10.1111/j.1365-2125.2010.03774.x
PMCID:
PMC3093074
Abstract Full Text PDF–1.1M
Delayed drug hypersensitivity: models of T-cell stimulation
Jacqueline Adam, Werner J Pichler, Daniel Yerly
Br J Clin Pharmacol. 2011 May; 71(5): 701–707. doi: 10.1111/j.1365-2125.2010.03764.x
PMCID:
PMC3093075
Abstract Full Text PDF–750K

Pharmacodynamics

The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men
Bart J Van der Schueren, Rebecca Blanchard, M Gail Murphy, John Palcza, Inge De Lepeleire, Anne Van Hecken, Marleen Depré, Jan N de Hoon
Br J Clin Pharmacol. 2011 May; 71(5): 708–717. doi: 10.1111/j.1365-2125.2010.03869.x
PMCID:
PMC3093076
Abstract Full Text PDF–863K

Drug Interactions

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren
Tuija Tapaninen, Pertti J Neuvonen, Mikko Niemi
Br J Clin Pharmacol. 2011 May; 71(5): 718–726. doi: 10.1111/j.1365-2125.2010.03898.x
PMCID:
PMC3093077
Abstract Full Text PDF–851K
Perpetrators of pharmacokinetic drug–drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment
Thomas M Polasek, Frank P Y Lin, John O Miners, Matthew P Doogue
Br J Clin Pharmacol. 2011 May; 71(5): 727–736. doi: 10.1111/j.1365-2125.2011.03903.x
PMCID:
PMC3093078
Abstract Full Text PDF–825K Supplementary Material

Pharmacogenetics

Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Joanne S L Lim, Xiang A Chen, Onkar Singh, Yoon S Yap, Raymond C H Ng, Nan S Wong, Mabel Wong, Edmund J D Lee, Balram Chowbay
Br J Clin Pharmacol. 2011 May; 71(5): 737–750. doi: 10.1111/j.1365-2125.2011.03905.x
PMCID:
PMC3093079
Abstract Full Text PDF–1.0M

Paediatric Clinical Pharmacology

Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactions
Lise Aagaard, Ebba Holme Hansen
Br J Clin Pharmacol. 2011 May; 71(5): 751–757. doi: 10.1111/j.1365-2125.2011.03915.x
PMCID:
PMC3093080
Abstract Full Text PDF–627K

Drug Safety

Cannabis-related hospitalizations: unexpected serious events identified through hospital databases
Emilie Jouanjus, Florence Leymarie, Marie Tubery, Maryse Lapeyre-Mestre
Br J Clin Pharmacol. 2011 May; 71(5): 758–765. doi: 10.1111/j.1365-2125.2010.03897.x
PMCID:
PMC3093081
Abstract Full Text PDF–724K

Pharmacoepidemiology

Statin adherence and the risk of major coronary events in patients with diabetes: a nested case–control study
Päivi Ruokoniemi, Maarit J Korhonen, Arja Helin-Salmivaara, Piia Lavikainen, Antti Jula, Seppo Y T Junnila, Raimo Kettunen, Risto Huupponen
Br J Clin Pharmacol. 2011 May; 71(5): 766–776. doi: 10.1111/j.1365-2125.2010.03895.x
PMCID:
PMC3093082
Abstract Full Text PDF–893K

Short Reports

Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy
Biswa M Padhy, Saravana P Shanmugam, Yogendra K Gupta, Aman Goyal
Br J Clin Pharmacol. 2011 May; 71(5): 777–779. doi: 10.1111/j.1365-2125.2010.03893.x
PMCID:
PMC3093083
Abstract Full Text PDF–413K
Outcomes of a decision support prompt in community pharmacy-dispensing software to promote step-down of proton pump inhibitor therapy
Colin Curtain, Gregory M Peterson, Peter Tenni, Ivan K Bindoff, Mackenzie Williams
Br J Clin Pharmacol. 2011 May; 71(5): 780–784. doi: 10.1111/j.1365-2125.2010.03890.x
PMCID:
PMC3093084
Abstract Full Text PDF–558K

Letters to the Editors

What's in a name?
Geoffrey T Tucker, John O Miners
Br J Clin Pharmacol. 2011 May; 71(5): 785–786. doi: 10.1111/j.1365-2125.2010.03817.x
PMCID:
PMC3093085
Full Text PDF–348K
Integrating pharmacology and clinical pharmacology
Jeffrey K Aronson
Br J Clin Pharmacol. 2011 May; 71(5): 787–790. doi: 10.1111/j.1365-2125.2011.03910.x
PMCID:
PMC3093086
Full Text PDF–461K

Book Review

A Clinical Trials Manual from the Duke Clinical Research Institute. Lessons from a horse named Jim
Dipti Amin
Br J Clin Pharmacol. 2011 May; 71(5): 791–792. doi: 10.1111/j.1365-2125.2010.03888.x
PMCID:
PMC3093087
Full Text PDF–348K
Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk